vs
Side-by-side financial comparison of PATHWARD FINANCIAL, INC. (CASH) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($196.9M vs $173.1M, roughly 1.1× PATHWARD FINANCIAL, INC.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs -0.2%). PATHWARD FINANCIAL, INC. produced more free cash flow last quarter ($104.1M vs $43.5M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs -18.0%).
Pathward Financial, Inc. is a U.S.-based banking and financial services company. It adopted its current name in 2022 after its parent, Meta Financial Group, sold the "Meta" trademark to Meta Platforms.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
CASH vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $173.1M | $196.9M |
| Net Profit | $35.2M | — |
| Gross Margin | — | 79.5% |
| Operating Margin | 24.6% | 1.2% |
| Net Margin | 20.3% | — |
| Revenue YoY | -0.2% | 5.1% |
| Net Profit YoY | 11.9% | — |
| EPS (diluted) | $1.57 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $173.1M | $196.9M | ||
| Q3 25 | $186.7M | $179.5M | ||
| Q2 25 | $195.8M | $181.1M | ||
| Q1 25 | $274.8M | $168.9M | ||
| Q4 24 | $182.6M | $187.3M | ||
| Q3 24 | $179.5M | $168.6M | ||
| Q2 24 | $188.6M | $178.0M | ||
| Q1 24 | $257.6M | $167.1M |
| Q4 25 | $35.2M | — | ||
| Q3 25 | $38.8M | $5.4M | ||
| Q2 25 | $42.1M | $-4.8M | ||
| Q1 25 | $75.0M | $4.8M | ||
| Q4 24 | $30.0M | — | ||
| Q3 24 | $33.5M | $-143.5M | ||
| Q2 24 | $44.9M | $18.9M | ||
| Q1 24 | $69.9M | $9.0M |
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% | ||
| Q1 24 | — | 71.6% |
| Q4 25 | 24.6% | 1.2% | ||
| Q3 25 | 25.9% | 3.5% | ||
| Q2 25 | 24.1% | 4.7% | ||
| Q1 25 | 33.2% | 1.2% | ||
| Q4 24 | 19.8% | 13.2% | ||
| Q3 24 | 20.9% | -82.8% | ||
| Q2 24 | 27.1% | 15.9% | ||
| Q1 24 | 33.8% | 7.9% |
| Q4 25 | 20.3% | — | ||
| Q3 25 | 20.8% | 3.0% | ||
| Q2 25 | 21.5% | -2.7% | ||
| Q1 25 | 27.3% | 2.8% | ||
| Q4 24 | 16.4% | — | ||
| Q3 24 | 18.7% | -85.1% | ||
| Q2 24 | 23.8% | 10.6% | ||
| Q1 24 | 27.1% | 5.4% |
| Q4 25 | $1.57 | $0.05 | ||
| Q3 25 | $1.69 | $0.12 | ||
| Q2 25 | $1.81 | $-0.11 | ||
| Q1 25 | $3.14 | $0.10 | ||
| Q4 24 | $1.23 | $0.38 | ||
| Q3 24 | $1.34 | $-3.11 | ||
| Q2 24 | $1.78 | $0.39 | ||
| Q1 24 | $2.74 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $331.2M | $238.4M |
| Total DebtLower is stronger | $33.5M | $372.2M |
| Stockholders' EquityBook value | $854.5M | $693.1M |
| Total Assets | $7.6B | $1.3B |
| Debt / EquityLower = less leverage | 0.04× | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $331.2M | $238.4M | ||
| Q3 25 | $120.6M | $246.3M | ||
| Q2 25 | $258.3M | $445.9M | ||
| Q1 25 | $254.2M | $493.6M | ||
| Q4 24 | $597.4M | $484.6M | ||
| Q3 24 | $158.3M | $453.8M | ||
| Q2 24 | $298.9M | $404.2M | ||
| Q1 24 | $347.9M | $325.9M |
| Q4 25 | $33.5M | $372.2M | ||
| Q3 25 | $33.5M | $376.7M | ||
| Q2 25 | $33.4M | $580.5M | ||
| Q1 25 | $33.4M | $583.4M | ||
| Q4 24 | $33.4M | $585.3M | ||
| Q3 24 | $33.4M | — | ||
| Q2 24 | $33.3M | — | ||
| Q1 24 | $33.4M | — |
| Q4 25 | $854.5M | $693.1M | ||
| Q3 25 | $858.0M | $727.2M | ||
| Q2 25 | $819.0M | $757.8M | ||
| Q1 25 | $814.7M | $798.5M | ||
| Q4 24 | $758.3M | $778.3M | ||
| Q3 24 | $822.5M | $749.6M | ||
| Q2 24 | $748.4M | $879.3M | ||
| Q1 24 | $719.5M | $892.2M |
| Q4 25 | $7.6B | $1.3B | ||
| Q3 25 | $7.2B | $1.3B | ||
| Q2 25 | $7.2B | $1.5B | ||
| Q1 25 | $7.0B | $1.6B | ||
| Q4 24 | $7.6B | $1.6B | ||
| Q3 24 | $7.5B | $1.5B | ||
| Q2 24 | $7.5B | $1.6B | ||
| Q1 24 | $7.4B | $1.6B |
| Q4 25 | 0.04× | 0.54× | ||
| Q3 25 | 0.04× | 0.52× | ||
| Q2 25 | 0.04× | 0.77× | ||
| Q1 25 | 0.04× | 0.73× | ||
| Q4 24 | 0.04× | 0.75× | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.04× | — | ||
| Q1 24 | 0.05× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.3M | $43.7M |
| Free Cash FlowOCF − Capex | $104.1M | $43.5M |
| FCF MarginFCF / Revenue | 60.1% | 22.1% |
| Capex IntensityCapex / Revenue | 2.4% | 0.1% |
| Cash ConversionOCF / Net Profit | 3.08× | — |
| TTM Free Cash FlowTrailing 4 quarters | $616.8M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.3M | $43.7M | ||
| Q3 25 | $303.7M | $60.8M | ||
| Q2 25 | $30.4M | $12.0M | ||
| Q1 25 | $188.3M | $35.5M | ||
| Q4 24 | $-71.7M | $33.1M | ||
| Q3 24 | $143.1M | $53.9M | ||
| Q2 24 | $113.2M | $53.2M | ||
| Q1 24 | $203.0M | $49.1M |
| Q4 25 | $104.1M | $43.5M | ||
| Q3 25 | $300.3M | $57.0M | ||
| Q2 25 | $27.7M | $9.3M | ||
| Q1 25 | $184.7M | $26.9M | ||
| Q4 24 | $-73.8M | $31.0M | ||
| Q3 24 | $138.8M | $49.8M | ||
| Q2 24 | $111.0M | $51.6M | ||
| Q1 24 | $201.3M | $46.3M |
| Q4 25 | 60.1% | 22.1% | ||
| Q3 25 | 160.9% | 31.7% | ||
| Q2 25 | 14.1% | 5.1% | ||
| Q1 25 | 67.2% | 15.9% | ||
| Q4 24 | -40.4% | 16.6% | ||
| Q3 24 | 77.3% | 29.6% | ||
| Q2 24 | 58.8% | 29.0% | ||
| Q1 24 | 78.1% | 27.7% |
| Q4 25 | 2.4% | 0.1% | ||
| Q3 25 | 1.8% | 2.2% | ||
| Q2 25 | 1.4% | 1.5% | ||
| Q1 25 | 1.3% | 5.1% | ||
| Q4 24 | 1.1% | 1.1% | ||
| Q3 24 | 2.4% | 2.4% | ||
| Q2 24 | 1.2% | 0.9% | ||
| Q1 24 | 0.7% | 1.7% |
| Q4 25 | 3.08× | — | ||
| Q3 25 | 7.83× | 11.20× | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 2.51× | 7.37× | ||
| Q4 24 | -2.39× | — | ||
| Q3 24 | 4.27× | — | ||
| Q2 24 | 2.52× | 2.82× | ||
| Q1 24 | 2.90× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CASH
| Consumer | $103.0M | 59% |
| Payment Card And Deposit Fees | $30.1M | 17% |
| Other | $24.2M | 14% |
| Rental Income | $11.6M | 7% |
| Commercial | $4.2M | 2% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
